12-03-04

Express Mail No. EV519867003US

INFORMATION DISCLOSURE
STATEMENT
under 37 CFR § 1.97(p)
BE'W
الما من الما
DEC 0 1 2004 SEE
Address to:
Mail Stop AF
Commissioner for Patents
D O Poy 1450

/ Maii No. E v 317807003CS				
Attorney Docket	BEAR-006	7		
First Named Inventor	YONEDA, TOSHIYUKI			
Application Number	09/641,034			
Filing Date	August 16, 2000			
Group Art Unit	1653			
Examiner Name	WAX, ROBERT A.	-		

Title:

"INTEGRIN BINDING MOTIF CONTAINING PEPTIDES AND METHODS OF TREATING

SKELETAL DISEASES"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed after a Final Action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

A Form SB08 (substitute for form 1449) listing the references accompanies this paper. Applicants would appreciate the Examiner initialing and returning the form to indicate that the references have been reviewed and made of record.

Statement(s) under 37 CFR § 1.97(e):

- (I) That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- (2) That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

12/06/2004 LWONDIM1 00000007 500815 09641034

01 FC:1806 180.00 DA

Atty Dkt. No.: BEAR-006 USSN: 09/641,034

In accordance with the requirements of 37 C.F.R. §1.97(d) accompanying this paper is a certification as specified in 37 C.F.R. §1.97(e). Applicant(s) hereby petition for the consideration of this Information Disclosure Statement.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) to cover the petition accompanies this disclosure statement. The Office is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to our Deposit Account No. 50-0815, Order No. BEAR -006 may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date:

By:

Karl Bozicevic/Reg. No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650)327-3231

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OE VO Substitute	e for form 1449B/PTO			Complete if Known		
(1)				Application Number	09/641,034	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	August 16, 2000	
01000				First Named Inventor	YONEDA, TOSHIYUKI	
Mer S				Group Art Unit	1653	
· ·	(use as many sheets as necessary)			Examiner Name	WAX, ROBERT A.	
Sheet & The Sheet	1	of	1	Attorney Docket Number	BEAR-006	

Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
		Lopez-Moratalla et al., "A common structural motif in immunopotentiating peptides with sequences present in human autoantigens. Elicitation of a response mediated by monocytes and Th1 cells" Biochimica et Biophysica Acta, Vol. 1317, No. 3, 1996, pgs. 183-191	
-			
		,	
	-		
· 			
xaminer Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.